Debio 4228

DRUG2 trials

Sponsors

Debiopharm International SA

Conditions

Prostate Canceradvanced prostate cancer

Phase 2

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

CompletedNCT06395753

Debiopharm International SAProstate Cancer

Start: 2024-05-23End: 2026-07-22Updated: 2026-08-24

A Phase 2, randomized, open-label, dose-finding study of Debio 4228, an extended-release formulation of gonadotropin-releasing hormone antagonist in participants with advanced prostate cancer

Active, not recruitingCTIS2024-511038-11-00

Debiopharm International SAadvanced prostate cancer

Start: 2024-09-24Target: 41Updated: 2025-11-24